comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-03 06:17:53 - browse：5173

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Popular nasal decongestant doesn't actually relieve congestion

WSS

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Christmas in the PICU brings some surprising joy

Virtual care provider acquires bankrupt Pear's prescription apps

SEC charges former device maker CEO with $41 million fraud

Telehealth for opioid use disorder is lifesaving

How medical schools plan to diversify without affirmative action

hotspot

comprehensive

leisure time

In Memoriam: Notable people who died in 2023

Acelyrin, a rare IPO success, stumbles in its first big test

Dobbs anniversary: the lost opportunity of abortion as health care

Hospitals consider fixing cancer drug shortages on their own

Malaria cases in Florida and Texas: Here’s what you need to know

Diverse clinical trials: Why aren’t we there yet?

Anesthesiologist group: stop taking Ozempic before surgery

Walmart eyes Medicare Advantage provider ChenMed

Medicare details structure of new drug price negotiation program

Albert Bourla of Pfizer: worst biopharma CEO of 2023

explore

CRISPR gene editing developments we’re watching in 2024

Medicare Advantage beneficiaries sue Humana over algorithm use

Medicare drug price negotiation hasn't dried up venture capital

Private equity could exacerbate cardiology's overuse problem, experts fear

Virtual care provider acquires bankrupt Pear's prescription apps

In Spain, a hospital brews its own CAR

Wikipedia

hotspot

focus

focus